-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com
Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com
Stock analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Wednesday. The firm set a "sell" rating on the biotechnology company's stock.
GNCA has been the subject of a number of other reports. HC Wainwright downgraded Genocea Biosciences from a "buy" rating to a "neutral" rating in a research report on Friday, April 29th. Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a research note on Friday, April 29th.
Get Genocea Biosciences alerts:Genocea Biosciences Price Performance
Genocea Biosciences stock opened at $0.01 on Wednesday. The firm has a 50 day moving average of $0.01 and a 200 day moving average of $0.47. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.20. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
Insiders Place Their Bets
In other Genocea Biosciences news, Director Ali Behbahani sold 4,445,093 shares of the firm's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total value of $355,607.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Paul Edward Walker sold 5,931,843 shares of Genocea Biosciences stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $0.07, for a total transaction of $415,229.01. Following the completion of the sale, the insider now owns 4,445,093 shares of the company's stock, valued at $311,156.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ali Behbahani sold 4,445,093 shares of Genocea Biosciences stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $0.08, for a total value of $355,607.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,537,612 shares of company stock valued at $781,461. 1.61% of the stock is currently owned by corporate insiders.Institutional Inflows and Outflows
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC grew its holdings in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 59.25% of the company's stock.
About Genocea Biosciences
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Featured Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Institutional Support For TJX Companies May Cap Gains
- If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
- Is Sanofi A Buy, Despite Recent Stumbles?
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ's Wholesale Club Pops, Will Costco Be Next?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Stock analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Wednesday. The firm set a "sell" rating on the biotechnology company's stock.
斯托克新闻网的股票分析师在周三发布的一份报告中假设了Genocea Biosciences(纳斯达克代码:GNCA-GET Rating)的股票。该公司对这家生物技术公司的股票设定了“卖出”评级。
GNCA has been the subject of a number of other reports. HC Wainwright downgraded Genocea Biosciences from a "buy" rating to a "neutral" rating in a research report on Friday, April 29th. Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a research note on Friday, April 29th.
GNCA一直是其他一些报告的主题。在4月29日周五发布的一份研究报告中,HC Wainwright将Genocea Biosciences的评级从买入下调至中性。Stifel Nicolaus在4月29日星期五的一份研究报告中将Genocea Biosciences的评级从“买入”下调至“持有”。
Genocea Biosciences Price Performance
Genocea Bioscions价格表现
Genocea Biosciences stock opened at $0.01 on Wednesday. The firm has a 50 day moving average of $0.01 and a 200 day moving average of $0.47. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.20. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
Genocea Biosciences的股票周三开盘报0.01美元。该公司的50日移动均线切入位在0.01美元,200日移动均线切入位在0.47美元。Genocea Biosciences的12个月低点为0.01美元,12个月高位为2.20美元。该公司的债务权益比为0.24,流动比率为1.35,速动比率为1.35。
Insiders Place Their Bets
内部人士下注
Institutional Inflows and Outflows
机构资金流入和流出
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC grew its holdings in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 59.25% of the company's stock.
一家机构投资者最近提高了对Genocea Biosciences股票的头寸。根据英联邦股票服务公司在最近提交给美国证券交易委员会的13F文件中的数据,该公司在第四季度增持了Genocea Biosciences,Inc.(纳斯达克代码:GNCA-GET评级)49.4%的股份。该基金持有这家生物技术公司31,981股股票,在此期间又购买了10,576股。截至最近向美国证券交易委员会提交的文件,英联邦股权服务公司拥有Genocea Biosciences公司约0.06%的股份,价值3.7万美元。对冲基金和其他机构投资者持有该公司59.25%的股票。
About Genocea Biosciences
关于Genocea生物科学
(Get Rating)
(获取评级)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences,Inc.是一家生物制药公司,发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS,该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Institutional Support For TJX Companies May Cap Gains
- If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
- Is Sanofi A Buy, Despite Recent Stumbles?
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ's Wholesale Club Pops, Will Costco Be Next?
- 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
- 对TJX公司的机构支持可能限制涨幅
- 如果你讨厌超速摄像头,那么你会喜欢Verra Mobility Stock
- 尽管赛诺菲最近跌跌撞撞,但它是买入的吗?
- 星巴克股票,品牌忠诚度足以成为购买理由吗
- BJ‘s批发俱乐部流行音乐,Costco会是下一个吗?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧